Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Publisher Correction: Combating subclonal evolution of resistant cancer phenotypes.

Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH.

Nat Commun. 2018 Feb 5;9(1):572. doi: 10.1038/s41467-017-02383-6.

2.

Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer.

King CJ, Woodward J, Schwartzman J, Coleman DJ, Lisac R, Wang NJ, Van Hook K, Gao L, Urrutia J, Dane MA, Heiser LM, Alumkal JJ.

Oncotarget. 2017 Nov 20;8(67):111084-111095. doi: 10.18632/oncotarget.22560. eCollection 2017 Dec 19.

3.

The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations.

Keenan AB, Jenkins SL, Jagodnik KM, Koplev S, He E, Torre D, Wang Z, Dohlman AB, Silverstein MC, Lachmann A, Kuleshov MV, Ma'ayan A, Stathias V, Terryn R, Cooper D, Forlin M, Koleti A, Vidovic D, Chung C, Schürer SC, Vasiliauskas J, Pilarczyk M, Shamsaei B, Fazel M, Ren Y, Niu W, Clark NA, White S, Mahi N, Zhang L, Kouril M, Reichard JF, Sivaganesan S, Medvedovic M, Meller J, Koch RJ, Birtwistle MR, Iyengar R, Sobie EA, Azeloglu EU, Kaye J, Osterloh J, Haston K, Kalra J, Finkbiener S, Li J, Milani P, Adam M, Escalante-Chong R, Sachs K, Lenail A, Ramamoorthy D, Fraenkel E, Daigle G, Hussain U, Coye A, Rothstein J, Sareen D, Ornelas L, Banuelos M, Mandefro B, Ho R, Svendsen CN, Lim RG, Stocksdale J, Casale MS, Thompson TG, Wu J, Thompson LM, Dardov V, Venkatraman V, Matlock A, Van Eyk JE, Jaffe JD, Papanastasiou M, Subramanian A, Golub TR, Erickson SD, Fallahi-Sichani M, Hafner M, Gray NS, Lin JR, Mills CE, Muhlich JL, Niepel M, Shamu CE, Williams EH, Wrobel D, Sorger PK, Heiser LM, Gray JW, Korkola JE, Mills GB, LaBarge M, Feiler HS, Dane MA, Bucher E, Nederlof M, Sudar D, Gross S, Kilburn DF, Smith R, Devlin K, Margolis R, Derr L, Lee A, Pillai A.

Cell Syst. 2018 Jan 24;6(1):13-24. doi: 10.1016/j.cels.2017.11.001. Epub 2017 Nov 29. Review.

PMID:
29199020
4.

MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance.

Farrell AS, Joly MM, Allen-Petersen BL, Worth PJ, Lanciault C, Sauer D, Link J, Pelz C, Heiser LM, Morton JP, Muthalagu N, Hoffman MT, Manning SL, Pratt ED, Kendsersky ND, Egbukichi N, Amery TS, Thoma MC, Jenny ZP, Rhim AD, Murphy DJ, Sansom OJ, Crawford HC, Sheppard BC, Sears RC.

Nat Commun. 2017 Nov 23;8(1):1728. doi: 10.1038/s41467-017-01967-6.

5.

Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics.

Hafner M, Heiser LM, Williams EH, Niepel M, Wang NJ, Korkola JE, Gray JW, Sorger PK.

Sci Data. 2017 Nov 7;4:170166. doi: 10.1038/sdata.2017.166.

6.

Combating subclonal evolution of resistant cancer phenotypes.

Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH.

Nat Commun. 2017 Nov 1;8(1):1231. doi: 10.1038/s41467-017-01174-3. Erratum in: Nat Commun. 2018 Feb 5;9(1):572.

7.

Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

Korkola JE, Collisson EA, Heiser LM, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW.

PLoS One. 2017 Oct 11;12(10):e0186551. doi: 10.1371/journal.pone.0186551. eCollection 2017.

8.

Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer.

Hassan S, Esch A, Liby T, Gray JW, Heiser LM.

Mol Cancer Ther. 2017 Dec;16(12):2892-2901. doi: 10.1158/1535-7163.MCT-17-0170. Epub 2017 Sep 27.

PMID:
28958991
9.

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.

Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R.

Clin Cancer Res. 2017 Sep 1;23(17):5123-5134. doi: 10.1158/1078-0432.CCR-16-2191. Epub 2017 May 9.

PMID:
28487443
10.

Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes.

Rahman M, MacNeil SM, Jenkins DF, Shrestha G, Wyatt SR, McQuerry JA, Piccolo SR, Heiser LM, Gray JW, Johnson WE, Bild AH.

Genome Med. 2017 Apr 26;9(1):40. doi: 10.1186/s13073-017-0429-x.

11.

Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, Dane MA, Esch A, Feiler HS, Wang NJ, Hardwicke MA, Laquerre S, Jackson J, Wood KW, Weber B, Spellman PT, Aparicio S, Wooster R, Caldas C, Gray JW.

Breast Cancer Res. 2017 Feb 9;19(1):17. doi: 10.1186/s13058-017-0809-6. No abstract available.

12.

Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling.

Hill SM, Nesser NK, Johnson-Camacho K, Jeffress M, Johnson A, Boniface C, Spencer SE, Lu Y, Heiser LM, Lawrence Y, Pande NT, Korkola JE, Gray JW, Mills GB, Mukherjee S, Spellman PT.

Cell Syst. 2017 Jan 25;4(1):73-83.e10. doi: 10.1016/j.cels.2016.11.013. Epub 2016 Dec 22.

13.

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, Tsimelzon A, Gutierrez C, Huang S, Edwards DP, Trivedi MV, Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne CK, Schiff R.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6600-E6609. Epub 2016 Oct 6.

14.

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.

Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, Heiser LM, Alumkal JJ.

Oncotarget. 2016 Jun 28;7(26):40690-40703. doi: 10.18632/oncotarget.9816.

15.

PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder.

Brown A, Patel S, Ward C, Lorenz A, Ortiz M, DuRoss A, Wieghardt F, Esch A, Otten EG, Heiser LM, Korolchuk VI, Sun C, Sarkar S, Sahay G.

Sci Rep. 2016 Aug 30;6:31750. doi: 10.1038/srep31750.

16.

Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, Dane MA, Esch A, Feiler HS, Wang NJ, Hardwicke MA, Laquerre S, Jackson J, W Wood K, Weber B, Spellman PT, Aparicio S, Wooster R, Caldas C, Gray JW.

Breast Cancer Res. 2016 Jul 1;18(1):70. doi: 10.1186/s13058-016-0728-y. Erratum in: Breast Cancer Res. 2017 Feb 9;19(1):17.

17.

Inferring causal molecular networks: empirical assessment through a community-based effort.

Hill SM, Heiser LM, Cokelaer T, Unger M, Nesser NK, Carlin DE, Zhang Y, Sokolov A, Paull EO, Wong CK, Graim K, Bivol A, Wang H, Zhu F, Afsari B, Danilova LV, Favorov AV, Lee WS, Taylor D, Hu CW, Long BL, Noren DP, Bisberg AJ; HPN-DREAM Consortium, Mills GB, Gray JW, Kellen M, Norman T, Friend S, Qutub AA, Fertig EJ, Guan Y, Song M, Stuart JM, Spellman PT, Koeppl H, Stolovitzky G, Saez-Rodriguez J, Mukherjee S.

Nat Methods. 2016 Apr;13(4):310-8. doi: 10.1038/nmeth.3773. Epub 2016 Feb 22.

18.

A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity.

Laderas TG, Heiser LM, Sönmez K.

Front Genet. 2015 Dec 23;6:341. doi: 10.3389/fgene.2015.00341. eCollection 2015.

19.

Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.

Lue HW, Cole B, Rao SA, Podolak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, Heiser LM, Tyner JW, Thomas GV.

Oncotarget. 2015 Dec 29;6(42):44675-87. doi: 10.18632/oncotarget.5971.

20.

Macular Diplopia.

Shippman S, Cohen KR, Heiser L.

Am Orthopt J. 2015;65:26-30. doi: 10.3368/aoj.65.1.26. Review.

PMID:
26564922
21.

Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics.

Goodspeed A, Heiser LM, Gray JW, Costello JC.

Mol Cancer Res. 2016 Jan;14(1):3-13. doi: 10.1158/1541-7786.MCR-15-0189. Epub 2015 Aug 6. Review.

22.

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.

Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Lopez-Tarruella S, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff R.

Clin Cancer Res. 2015 Sep 1;21(17):3995-4003. doi: 10.1158/1078-0432.CCR-14-2728. Epub 2015 May 26.

23.

Erratum to: Modeling precision treatment of breast cancer.

Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW.

Genome Biol. 2015 May 12;16:95. doi: 10.1186/s13059-015-0658-5.

24.

A community computational challenge to predict the activity of pairs of compounds.

Bansal M, Yang J, Karan C, Menden MP, Costello JC, Tang H, Xiao G, Li Y, Allen J, Zhong R, Chen B, Kim M, Wang T, Heiser LM, Realubit R, Mattioli M, Alvarez MJ, Shen Y; NCI-DREAM Community, Gallahan D, Singer D, Saez-Rodriguez J, Xie Y, Stolovitzky G, Califano A; NCI-DREAM Community.

Nat Biotechnol. 2014 Dec;32(12):1213-22. doi: 10.1038/nbt.3052. Epub 2014 Nov 17.

25.

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.

Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.

Breast Cancer Res. 2014 Sep 11;16(5):430. doi: 10.1186/s13058-014-0430-x.

26.

A community effort to assess and improve drug sensitivity prediction algorithms.

Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, Bansal M, Ammad-ud-din M, Hintsanen P, Khan SA, Mpindi JP, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K; NCI DREAM Community, Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G.

Nat Biotechnol. 2014 Dec;32(12):1202-12. doi: 10.1038/nbt.2877. Epub 2014 Jun 1.

27.

Distinct cervical microRNA profiles are present in women destined to have a preterm birth.

Elovitz MA, Brown AG, Anton L, Gilstrop M, Heiser L, Bastek J.

Am J Obstet Gynecol. 2014 Mar;210(3):221.e1-11. doi: 10.1016/j.ajog.2013.12.043.

PMID:
24565431
28.

Modeling precision treatment of breast cancer.

Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, van't Veer LJ, Spellman PT, Gray JW.

Genome Biol. 2013;14(10):R110. Erratum in: Genome Biol. 2015;16:95.

29.

A robust prognostic signature for hormone-positive node-negative breast cancer.

Griffith OL, Pepin F, Enache OM, Heiser LM, Collisson EA, Spellman PT, Gray JW.

Genome Med. 2013 Oct 11;5(10):92. doi: 10.1186/gm496. eCollection 2013.

30.

Metrics other than potency reveal systematic variation in responses to cancer drugs.

Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK.

Nat Chem Biol. 2013 Nov;9(11):708-14. doi: 10.1038/nchembio.1337. Epub 2013 Sep 8.

31.

Biomarkers and cervical length to predict spontaneous preterm birth in asymptomatic high-risk women.

Bastek JA, Hirshberg A, Chandrasekaran S, Owen CM, Heiser LM, Araujo BA, McShea MA, Ryan ME, Elovitz MA.

Obstet Gynecol. 2013 Aug;122(2 Pt 1):283-9. doi: 10.1097/AOG.0b013e31829ab714.

PMID:
23969796
32.

ATM suppresses SATB1-induced malignant progression in breast epithelial cells.

Ordinario E, Han HJ, Furuta S, Heiser LM, Jakkula LR, Rodier F, Spellman PT, Campisi J, Gray JW, Bissell MJ, Kohwi Y, Kohwi-Shigematsu T.

PLoS One. 2012;7(12):e51786. doi: 10.1371/journal.pone.0051786. Epub 2012 Dec 10.

33.

Bayesian inference of signaling network topology in a cancer cell line.

Hill SM, Lu Y, Molina J, Heiser LM, Spellman PT, Speed TP, Gray JW, Mills GB, Mukherjee S.

Bioinformatics. 2012 Nov 1;28(21):2804-10. doi: 10.1093/bioinformatics/bts514. Epub 2012 Aug 24.

34.

A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.

Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M.

Cancer Discov. 2012 Aug;2(8):685-93. Epub 2012 May 24.

35.

Subtype and pathway specific responses to anticancer compounds in breast cancer.

Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2724-9. doi: 10.1073/pnas.1018854108. Epub 2011 Oct 14.

36.

A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047.

Kuo WL, Das D, Ziyad S, Bhattacharya S, Gibb WJ, Heiser LM, Sadanandam A, Fontenay GV, Hu Z, Wang NJ, Bayani N, Feiler HS, Neve RM, Wyrobek AJ, Spellman PT, Marton LJ, Gray JW.

BMC Med. 2009 Dec 14;7:77. doi: 10.1186/1741-7015-7-77.

37.

Integrated analysis of breast cancer cell lines reveals unique signaling pathways.

Heiser LM, Wang NJ, Talcott CL, Laderoute KR, Knapp M, Guan Y, Hu Z, Ziyad S, Weber BL, Laquerre S, Jackson JR, Wooster RF, Kuo WL, Gray JW, Spellman PT.

Genome Biol. 2009;10(3):R31. doi: 10.1186/gb-2009-10-3-r31. Epub 2009 Mar 25.

38.

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.

Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM.

Cancer Res. 2009 Jan 15;69(2):565-72. doi: 10.1158/0008-5472.CAN-08-3389.

39.

"Double vision" as a presenting symptom in adults without acquired or long-standing strabismus.

Shippman S, Heiser L, Cohen KR, Hall L.

Am Orthopt J. 2008;58:92-8. doi: 10.3368/aoj.58.1.92.

PMID:
21149183
40.

Analysis of molecular inversion probe performance for allele copy number determination.

Wang Y, Moorhead M, Karlin-Neumann G, Wang NJ, Ireland J, Lin S, Chen C, Heiser LM, Chin K, Esserman L, Gray JW, Spellman PT, Faham M.

Genome Biol. 2007;8(11):R246.

41.

Dynamic circuitry for updating spatial representations. III. From neurons to behavior.

Berman RA, Heiser LM, Dunn CA, Saunders RC, Colby CL.

J Neurophysiol. 2007 Jul;98(1):105-21. Epub 2007 May 9.

42.

Spatial updating in area LIP is independent of saccade direction.

Heiser LM, Colby CL.

J Neurophysiol. 2006 May;95(5):2751-67. Epub 2005 Nov 16.

43.

Corollary discharge and spatial updating: when the brain is split, is space still unified?

Colby CL, Berman RA, Heiser LM, Saunders RC.

Prog Brain Res. 2005;149:187-205.

PMID:
16226585
44.

Dynamic circuitry for updating spatial representations. I. Behavioral evidence for interhemispheric transfer in the split-brain macaque.

Berman RA, Heiser LM, Saunders RC, Colby CL.

J Neurophysiol. 2005 Nov;94(5):3228-48. Epub 2005 May 11.

45.
46.

Dynamic visual acuity: its place in ophthalmology?

Shippman S, Heiser L, Cohen KR, Hall LS.

Am Orthopt J. 2005;55:139-43. doi: 10.3368/aoj.55.1.139.

PMID:
21149123
47.

Development of primary axial myopic anisometropia.

Shippman S, Heiser L, Hall LS, Cohen KR.

Am Orthopt J. 2003;53:109-14. doi: 10.3368/aoj.53.1.109.

PMID:
21149080

Supplemental Content

Loading ...
Support Center